To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

NCT00100074 | Unknown Phase 1

• 1 other identifier: NIDA-CPU-0007-1
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.

Conditions

Amphetamine-Related Disorders

Outcome Measures

Primary Outcomes (1)

• Safety

Interventions

Lobeline DRUG

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy individuals with a body mass index between 18 and 30.
• Willing and able to give written consent.
• Must have a negative drug test
• Females must have a negative pregnancy test prior to study drug administration
• Must have no medical contraindications as determined by routine testing

You may not qualify if:

• Please contact the site for more information

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA): lead

Study Sites (1)

U of CA, San Francisco

San Francisco, California, 94143, United States

Location

MeSH Terms

Conditions

Amphetamine-Related Disorders

Interventions

Lobeline

Condition Hierarchy (Ancestors)

Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Alkaloids; Heterocyclic Compounds; Piperidines; Heterocyclic Compounds, 1-Ring

Study Officials

• Reese Jones, M.D.

  Langley Porter Psychiatric Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Purpose: DIAGNOSTIC
• Sponsor Type: NIH

Study Record Dates

• First Submitted: December 22, 2004
• First Posted: December 23, 2004
• Study Start: September 1, 2004
• Study Completion: April 1, 2005
• Last Updated: January 11, 2017

Record last verified: 2004-12

Locations

US (1)